Clinical trial for Refractory Gout
Official title A Study of IN026 in Participants With Refractory Gout
ClinicalTrials.gov ID: NCT07587684
What this study is testing
What is IN026 Injection?
IN026 Injection is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for refractory gout.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are: What medical problems do participants have when taking IN026, such as changes in vital signs, blood tests, or heart rhythm?
- Phase 1: an early, usually small safety study
- Time commitment: about 20 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements.
- Male or female, 18-75 years old (inclusive) at screening.
- Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening.
- Serum uric acid ≥420 μmol/L (7 mg/dl) at screening.
- Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms)
You likely can't join if
- Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline.
- Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit.
- Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive...
- Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease.
- Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the...
See the full eligibility criteria
- Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements.
- Male or female, 18-75 years old (inclusive) at screening.
- Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening.
- Serum uric acid ≥420 μmol/L (7 mg/dl) at screening.
- Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms)
- Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline.
- Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit.
- Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis.
- Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease.
- Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric...
- Prolonged QTcF at screening.
- Uncontrolled or untreated hypertension at screening.
- Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents.
- History of severe allergy, or known allergy to IN026 or its components.
- Participation in other clinical trials within 30 days prior to screening.
- Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Wuhan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 20 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.